Mesa Laboratories, Inc.

NasdaqGS MLAB

Mesa Laboratories, Inc. Shareholders' Equity for the quarter ending September 30, 2024: USD 161.45 M

Mesa Laboratories, Inc. Shareholders' Equity is USD 161.45 M for the quarter ending September 30, 2024, a -58.36% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Mesa Laboratories, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 387.76 M, a 3.61% change year over year.
  • Mesa Laboratories, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 374.24 M, a -6.30% change year over year.
  • Mesa Laboratories, Inc. Shareholders' Equity for the quarter ending September 30, 2021 was USD 399.42 M, a 1.79% change year over year.
  • Mesa Laboratories, Inc. Shareholders' Equity for the quarter ending September 30, 2020 was USD 392.41 M, a 71.24% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
NasdaqGS: MLAB

Mesa Laboratories, Inc.

CEO Mr. Gary M. Owens
IPO Date Feb. 29, 1984
Location United States
Headquarters 12100 West Sixth Avenue
Employees 736
Sector Health Care
Industries
Description

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Similar companies

BMI

Badger Meter, Inc.

USD 209.78

1.49%

VPG

Vishay Precision Group, Inc.

USD 22.64

0.85%

VNT

Vontier Corporation

USD 36.35

1.65%

FTV

Fortive Corporation

USD 77.35

1.66%

ITRI

Itron, Inc.

USD 104.87

1.46%

ST

Sensata Technologies Holding plc

USD 27.74

1.02%

ESE

ESCO Technologies Inc.

USD 132.60

1.94%

NOVT

Novanta Inc.

USD 148.22

1.40%

COHR

Coherent, Inc.

USD 93.00

1.03%

StockViz Staff

January 15, 2025

Any question? Send us an email